Free shipping on all orders over $ 500

Pembrolizumab

Cat. No. M6102

All AbMole products are for research use only, cannot be used for human consumption.

Pembrolizumab Structure
Synonym:

Lambrolizumab; MK-3475

Size Price Availability Quantity
2mg USD 330  USD330 In stock
5mg USD 550  USD550 In stock
10mg USD 730  USD730 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. The binding of PD-1 with pembrolizumab was located on the C'D loop of PD-1. MW : 146.286 KD.

In addition to Melanoma and Lung carcinoma, pembrolizumab has also demonstrated efficacy in other advanced solid tumors and hematologic malignancies. Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer.

Chemical Information
CAS Number 1374853-91-4
Storage -80°C for long term
References

[1] Minan Wang, et al. FASEB J. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy

[2] Shuguang Tan, et al. Nat Commun. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab

[3] Reck M, et al. N Engl J Med. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

[4] Faghfuri E, et al. Expert Rev Anticancer Ther. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.

[5] Barbee MS, et al. Ann Pharmacother. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.

[6] Garon EB, et al. N Engl J Med. Pembrolizumab for the treatment of non-small-cell lung cancer.

Related PD-1/PD-L1 Products
PD-1/PD-L1-IN-9

PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model.

NSC622608 

NSC622608 is a V-domain Ig suppressor of T-cell activation (VISTA) ligand with an IC50 value of 4.8 μM.

PD-L1-IN-1 

PD-L1-IN-1 is a potent PD-L1 inhibitor with an IC50 of 115 nM.

SL-279252

SL-279252 (PD1-Fc-OX40L) is a hexameric, bi-functional fusion protein with an ECD of PD-1 (70 pM affinity to PD-L1) linked to the ECD of OX40L (324 pM affinity for OX40) through an Fc linker. SL-279252 exhibited linear PK at doses up to 3.0 mg/kg, and a greater than proportional increase in AUC was observed at 6.0 mg/kg suggesting potential receptor saturation. The preliminary half-life is approximately 23 hours.

Rosnilimab

Rosnilimab is a novel PD-1 checkpoint agonist antibody that reduces overactive T cell inflammation. Rosnilimab optimizes PD-1+ T cell inhibitory signaling by enabling tight immune synapse formation. Rosnilimab restores immune balance bringing T cell composition to a less activated state.

  Catalog
Abmole Inhibitor Catalog




Keywords: Pembrolizumab, Lambrolizumab; MK-3475 supplier, PD-1/PD-L1, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.